🏛️ Verified NIH Record • Updated 2026-08-19
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD) (NCT06924970)
A Phase 2, Double-blind, Randomized, Placebo-Controlled, Multicenter, Dose- Finding, Efficacy, and Safety Study of Tebapivat in Participants With Sickle Cell Disease
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Agios Pharmaceuticals, Inc.
🩺 Plain-English Summary (8th-Grade Level)
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
Who can join: Review the eligibility criteria below.
Location: UConn Health — Farmington, Connecticut
Age range: 16 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- UConn Health — Farmington, Connecticut
- MedStar Washington Hospital Center — Washington D.C., District of Columbia
- Emory-Children's Center/ Children's Healthcare of Atlanta: Arthur M. Blank Hospital — Atlanta, Georgia
- Henry Ford Health System — Detroit, Michigan
- Children's Hospital of Michigan — Detroit, Michigan
- Icahn School of Medicine at Mt. Sinai — New York, New York
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- Prisma Health Cancer Institute - Farris Road — Greenville, South Carolina
- University of Texas Health Science Center of Houston — Houston, Texas
- Fred Hutchinson Cancer Center, University of Washington — Seattle, Washington
- CHR de la Citadelle — Liège, Wallonne
- CHU Montreal — Montreal, Quebec
- Hôpital Edouard Herriot, CHU de Lyon — Lyon, Auvergne-Rhône-Alpes
- Institut Universitaire du Cancer de Toulouse - Oncopole — Toulouse, Midi Pyrenees
- CHU Hôpital Henri Mondor — Créteil, Île-de-France Region
- St. James Hospital — Dublin, Leinster
- Amsterdam Universitair Medisch Centrum, Locatie AMC — Amsterdam, North Holland
- Erasmus MC — Rotterdam, South Holland
- Universitair Medisch Centrum Utrecht — Utrecht,
- University College London — London,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Sickle Cell Disease
- Kidney Function in Sickle Cell Anemia — Chapel Hill, North Carolina
- BEACON: A Study Evaluating the Safety and Efficacy of BEAM-101 in Patients With Severe Sickle Cell Disease — Birmingham, Alabama
- Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease — Bethesda, Maryland
- Acupressure in Patients With Sickle Cell Disease — Irvine, California
- Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC) — Chicago, Illinois
- Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Severe Sickle Cell Disease (SCD) — Charlotte, North Carolina
Explore by condition: All Sickle Cell Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.